In a nutshell This study investigated cabozantinib (Cometriq), an anti-angiogenic drug, in the treatment of advanced and progressing prostate cancer. Researchers report preliminary evidence for cabozantinib in reducing disease progression and cancer pain. Some background Tumors need to be able to grow new blood vessels in order to grow....
Read MoreIn a nutshell This phase 2 trial aims to evaluate combinations of hormone therapies, a steroid drug, an immunotherapy drug, and chemotherapy in the treatment of metastatic castration-resistant prostate cancer. The main outcome to be investigated is overall survival (time from treatment until death from any cause). The trial is recruiting in Houston,...
Read More
In a nutshell This review analyzed platinum-based drugs in the treatment of advanced castration-resistant prostate cancer. While platinum-based drugs were often associated with various side effects, researchers reported moderate to good treatment effectivity in managing advanced prostate cancer. Some background Hormone therapy is the standard...
Read More
In a nutshell This study investigated the impact of surgery in patients with stage 4 (spread to other areas of the body) colorectal cancer who were treated with chemotherapy. Researchers reported that surgery increased survival in these patients. Some background Prior studies have reported increased survival in patients with stage 4...
Read More
In a nutshell This review evaluated current evidence on combination therapies for metastatic hormone-sensitive prostate cancer (mHSPC). Authors concluded that results are promising for the combination of taxane-based chemotherapies and alternative hormone therapies with androgen deprivation therapy (ADT). Some background ADT is a type of hormone...
Read More
In a nutshell This study investigated colorectal surgery as treatment option for metastatic (the cancer has spread to other organs) colorectal cancer. Researchers reported that colorectal surgery alone is associated with increased survival rates. Some background Roughly 20% of colorectal cancers are diagnosed once they have already spread. Prior...
Read MoreIn a nutshell The authors aimed to determine the effectiveness of enzalutamide (Xtandi ) in metastatic (cancer that has spread) hormone-resistant prostate cancer compared to the standard bicalutamide (Casodex) treatment. Some background Hormone deprivation therapy is a common treatment used in prostate cancer. It targets the...
Read More
In a nutshell This study aimed to assess the effectiveness of the anti-cancer drug erlotinib (Tarceva) in treating advanced non-small cell lung cancer (NSCLC) with positive EGFR mutations in caucasian patients. The study concluded that erlotinib was safe and effective as first-line treatment in this type of cancer. Some background A mutation...
Read More
In a nutshell This study investigated the impact of metabolic syndrome on treatment outcome with abiraterone acetate (Zytiga) for hormone-resistant prostate cancer. Researchers concluded that metabolic syndrome has an adverse outcome on disease progression in advanced prostate cancer. Some background Hormone therapy is a common treatment used in...
Read More
In a nutshell This study examined the effects of enzalutamide (Xtandi) in improving disease-related symptoms associated with advanced metastatic prostate cancer. The researchers concluded that enzalutamide treatment is effective in managing prostate cancer-derived bone tumors and pain among men with advanced prostate cancer. Some background When...
Read More
In a nutshell This study investigated the efficacy of necitumumab (Portrazza) and chemotherapy combined treatment for locally advanced (spread to the lymph nodes) or metastatic (spread to other areas of the body) colorectal cancer. Researchers suggested that this combination was effective in patients who had not previously been treated, with...
Read MoreIn a nutshell This review evaluated newly approved treatments for metastatic castration-resistant prostate cancer. Researchers concluded that a number of recently developed treatments provide a clinical benefit for men with metastatic castration-resistant prostate cancer. Some background Treatment for metastatic (cancer that has spread to...
Read More
